202983-32-2

202983-32-2 structure

Name: NF 279
Chemical Name: N-[4,6,8-tris(methylsulfonyl)naphthalen-1-yl]-4-[[4-[[4-[[4-[[4,6,8-tris(methylsulfonyl)naphthalen-1-yl]carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzamide
CAS Number: 202983-32-2
Molecular Formula: C₄₉H₃₀N₆Na₆O₂₃S₆
Molecular Weight: 1401.118
Catalog: Signaling Pathways Anti-infection HIV
Create Date: 2018-06-25 17:09:30
Modify Date: 2023-01-11 15:24:07
NF279 is a potent selective and reversible P2X1 receptor antagonist, with an IC50 of 19 nM. NF279 displays good selectivity over P2X2, P2X3 (IC50=1.62 μM), P2X4 (IC50>300 μM). NF279 is a dual HIV-1 coreceptor inhibitor that interferes with the functional engagement of CCR5 and CXCR4 by Env[1][2].

Name	N-[4,6,8-tris(methylsulfonyl)naphthalen-1-yl]-4-[[4-[[4-[[4-[[4,6,8-tris(methylsulfonyl)naphthalen-1-yl]carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzamide
Synonyms	cc-368 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis(imino-4,1-phenylenecarbonylimino-4,1-phenylenecarbonylimino)]bis-, sodium salt (1:6) Hexasodium 8-[(4-{[4-({[4-({4-[(4,6,8-trisulfonato-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl]carbamoyl}amino)benzoyl]amino}benzoyl)amino]naphthalene-1,3,5-trisulfonate Hexasodium 8,8'-[carbonylbis(imino-4,1-phenylenecarbonylimino-4,1-phenylenecarbonylimino)]di(1,3,5-naphthalenetrisulfonate) NF 279

Description	NF279 is a potent selective and reversible P2X1 receptor antagonist, with an IC50 of 19 nM. NF279 displays good selectivity over P2X2, P2X3 (IC50=1.62 μM), P2X4 (IC50>300 μM). NF279 is a dual HIV-1 coreceptor inhibitor that interferes with the functional engagement of CCR5 and CXCR4 by Env[1][2].
Related Catalog	Signaling Pathways >> Anti-infection >> HIV Research Areas >> Infection Signaling Pathways >> Membrane Transporter/Ion Channel >> P2X Receptor
Target	HIV
References	[1]. Rettinger J, Schmalzing G, Damer S, Müller G, Nickel P, Lambrecht G. The suramin analogue NF279 is a novel and potent antagonist selective for the P2X(1) receptor. Neuropharmacology. 2000;39(11):2044-2053. [2]. Giroud C, et al. P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions. J Virol. 2015;89(18):9368-9382.